Company Tagline
Live life again
Industry Category
Business Keywords
Company Description
Synklino is dedicated to enhancing the lives and long-term survival of transplant recipients. Located in Copenhagen, Capital Region of Denmark, Synklino is focused on providing rapid and safe solutions for the eradication of cytomegalovirus (CMV) infections, addressing a critical need in transplantation outcomes.
Synklino's innovative approach aims to eliminate CMV disease, which often leads to suboptimal transplantation results, increased morbidity, prolonged hospitalization, and higher mortality rates among transplant recipients. The company's leading drug candidate, SYN002, is designed to efficiently eliminate both lytic and latently infected cells, potently inhibiting viral replication and effectively removing the virus from the equation for transplant recipients.
Operating from its primary address at Frederiksborggade 1, 2.th. in Copenhagen, Synklino is committed to developing therapies that allow for both stand-alone and combination treatments. SYN002’s proven mechanism ensures highly potent, efficient, and selective elimination of CMV-infected cells. We invite the management of Synklino to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.
Synklino er dedikeret til at forbedre livet og den langsigtede overlevelse for transplantationsmodtagere. Beliggende i København, Hovedstadsregionen, Danmark, er Synklino fokuseret på at levere hurtige og sikre løsninger til udryddelse af cytomegalovirus (CMV) infektioner, hvilket adresserer et kritisk behov inden for transplantationsresultater.
Synklinos innovative tilgang sigter mod at eliminere CMV-sygdom, som ofte fører til suboptimale transplantationsresultater, øget morbiditet, forlænget hospitalsindlæggelse og højere dødelighed blandt transplantationsmodtagere. Virksomhedens førende lægemiddelkandidat, SYN002, er designet til effektivt at eliminere både lytiske og latent inficerede celler, hvilket kraftigt hæmmer viral replikation og effektivt fjerner virussen fra ligningen for transplantationsmodtagere.
Med udgangspunkt i sin primære adresse på Frederiksborggade 1, 2.th. i København, er Synklino engageret i at udvikle terapier, der giver mulighed for både enkeltstående og kombinationsbehandlinger. SYN002's dokumenterede mekanisme sikrer en yderst potent, effektiv og selektiv eliminering af CMV-inficerede celler. Vi inviterer ledelsen i Synklino til at oprette en skræddersyet og eksklusiv virksomhedspræsentation og produktliste på vores platform for yderligere at fremhæve deres banebrydende arbejde.
Key Personnel / Employees
Similar Companies
Other organizations in the same industry
xcellbio
Biotechnology-ResearchImproving therapeutic performance for predictive clinical outcomes through in vitro microenvironment...
CANSoR
Biotechnology-ResearchTransform the way we screen and diagnose cancer
Path Therapeutics, Inc.
Biotechnology-ResearchAccelerated drug discovery
ART-Biopharma LLC
Biotechnology-ResearchBiomedical research and biobanking company providing state-of-the-art biospecimens to pharma industr...
Alternative Company Names
This company is also known as